Login / Signup

Norepinephrine transporter analog benzylguanidine-conjugated nanoparticles for the delivery of paclitaxel in neuroblastoma.

Ozlem Ozen KarakusKavitha GoduguTaher A SalaheldinKazutoshi FujiokaShaker A Mousa
Published in: Nanomedicine (London, England) (2021)
Aim: We previously synthesized a polyethylene glycol-based norepinephrine transporter-targeted agent, BG-P-TAT, which has a benzylguanidine and a triazolyl-tetrac group. This targeted conjugate showed suppression of neuroblastoma tumor progression. In this study we aimed to synthesize nanoparticles to encapsulate the chemotherapeutic agent paclitaxel for targeting neuroblastoma tumors by using benzylguanidine so that it can compete with norepinephrine for uptake by neuroendocrine cells. Methods: Biocompatible poly(lactide-co-glycolic acid)-polyethylene glycol was chosen to prepare targeted nanoparticles for safe delivery of the chemotherapy agent paclitaxel. Result: Paclitaxel concentration was 60% higher in neuroblastoma tumors of mice treated with paclitaxel encapsulated in targeted nanoparticles than with non-targeted nanoparticles. Conclusion: These findings support the targeted delivery of paclitaxel as a chemotherapeutic agent for neuroblastoma.
Keyphrases
  • cancer therapy
  • chemotherapy induced
  • induced apoptosis
  • poor prognosis
  • photodynamic therapy
  • metabolic syndrome
  • skeletal muscle
  • cell death
  • ionic liquid
  • high fat diet induced
  • pi k akt